Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
On June 17, 2025, 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) held its 2025 virtual Annual Meeting of Stockholders. Of the 46.3 million outstanding shares, 38.5 million (≈83%) were represented in person or by proxy.
- Director elections (Proposal 1): All three Class II nominees were re-elected to serve until the 2028 AGM. Support ranged from 84.5% (Dr. Charles P. Theuer) to 98.9% (Susannah Gray).
- Auditor ratification (Proposal 2): Shareholders overwhelmingly confirmed PricewaterhouseCoopers LLP for FY 2025 (≈99.8% in favor).
- Say-on-pay (Proposal 3): 98.7% of votes cast approved FY 2024 executive compensation on an advisory basis.
- Say-on-pay frequency (Proposal 4): A majority (≈99%) selected one-year intervals for future advisory votes; the board will follow this cadence.
No other business or material transactions were reported. The results signal continued shareholder endorsement of the company’s leadership, compensation practices, and external auditor.